Private / Eli Lilly / Dorsey / Novartis / Lilly / Public R&D Investments / /
Country
United States / /
Currency
pence / USD / / /
Facility
Blood Institute / Rock Center / Management Columbia University / National Cancer Institute / Joshua S. Graff Zivin University of California / /
IndustryTerm
biotechnology firms / sector biopharmaceutical firms / cancer therapies / grant applications / pharmaceutical / biopharmaceutical industry / chemical compound / treatment for chronic myelogenous leukemia / biopharmaceutical firms / body systems / final commercial products / disease applications / cancer applications / fund applications / cell-signaling applications / pharmaceutical firms / /
MedicalCondition
particular disease / vascular disease / disease/science/time / similar disease / sepsis / cancer / tumors / disease / diabetes / entire disease / same disease / diseases / chronic myelogenous leukemia / specific disease / /
MedicalTreatment
cancer therapies / /
Organization
National Cancer Institute / Bhaven N. Sampat Department of Health Policy / Columbia University / National Institute of Health / School of Management / National Science Foundation / MIT / Harvard / Rock Center Boston / NATIONAL BUREAU OF ECONOMIC RESEARCH / National Heart / Lung / and Blood Institute / FDA / NBER Board of Directors / University of California / San Diego / /
Person
Joshua S. Graff Zivin Danielle Li / Scott Stern / Pierre Azoulay / Ben Jones / Jim Bessen / David Genesove / Jason Abaluck / David Autor / Joshua S. Graff Zivin / Heidi Williams / Naomi Hausman / Bhaven N. Sampat / Danielle Li / John Van Reenen / Alex Frankel / Kelly Shue / Pierre Azoulay Joshua / Joshua S. Graff / Danielle Li Bhaven / / /
Position
cancer researcher / Hunter / /
Product
Nokia E62 Smartphone / Gleevec / /
ProvinceOrState
New York / Massachusetts / /
Technology
biotechnology / cell signaling / biopharmaceuticals / drug discovery / gene expression / drug development / /
NBER WORKING PAPER SERIES PUBLIC R&D INVESTMENTS AND PRIVATE-SECTOR PATENTING: EVIDENCE FROM NIH FUNDING RULES Pierre Azoulay Joshua S. Graff Zivin